$PIRS
Pieris Pharmaceuticals Inc

2016 Q3 Form 10-Q Financial Statement

#000119312516679305 Filed on August 11, 2016

View on sec.gov

Income Statement

Concept 2016 Q3 2016 Q2 2015 Q2
Revenue $785.0K $1.073M $160.2K
YoY Change 89.34% 569.52% -77.05%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.340M $2.370M $1.970M
YoY Change 4.46% 20.3% -16.17%
% of Gross Profit
Research & Development $4.622M $4.500M $1.726M
YoY Change 125.28% 160.79% 54.22%
% of Gross Profit
Depreciation & Amortization $100.0K -$10.00K $70.00K
YoY Change 25.0% -114.29% -22.22%
% of Gross Profit
Operating Expenses $6.963M $6.868M $3.695M
YoY Change 62.14% 85.9% 230.2%
Operating Profit -$6.178M -$5.795M -$3.534M
YoY Change 59.23% 63.97% 27.6%
Interest Expense $0.00 $0.00 $53.00
YoY Change -100.0% -99.95%
% of Operating Profit
Other Income/Expense, Net -$18.24K -$87.80K $4.484K
YoY Change 845.72% -2058.1% 115.47%
Pretax Income -$6.196M -$5.883M -$3.530M
YoY Change 59.62% 66.66% 22.5%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.196M -$5.883M -$3.530M
YoY Change 57.98% 66.66% 22.5%
Net Earnings / Revenue -789.32% -548.37% -2202.89%
Basic Earnings Per Share
Diluted Earnings Per Share -$144.0K -$143.9K -$119.9K
COMMON SHARES
Basic Shares Outstanding 43.06M shares 39.83M shares 29.43M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2016 Q3 2016 Q2 2015 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.60M $40.40M $10.00M
YoY Change 13.31% 304.0%
Cash & Equivalents $36.56M $40.37M $10.03M
Short-Term Investments
Other Short-Term Assets $4.600M $3.500M $1.866M
YoY Change 257.97% 87.55%
Inventory
Prepaid Expenses $732.2K
Receivables
Other Receivables
Total Short-Term Assets $41.14M $43.88M $12.64M
YoY Change 20.46% 247.11%
LONG-TERM ASSETS
Property, Plant & Equipment $2.448M $2.447M $1.811M
YoY Change 26.94% 35.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $127.6K $127.3K $0.00
YoY Change 31.42%
Total Long-Term Assets $2.575M $2.574M $1.836M
YoY Change 25.64% 40.22%
TOTAL ASSETS
Total Short-Term Assets $41.14M $43.88M $12.64M
Total Long-Term Assets $2.575M $2.574M $1.836M
Total Assets $43.71M $46.45M $14.48M
YoY Change 20.75% 220.87%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.500M $1.600M $2.100M
YoY Change 309.09% -23.81%
Accrued Expenses $2.898M $2.325M $635.6K
YoY Change 180.33% 265.88%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $0.00
YoY Change
Total Short-Term Liabilities $9.952M $6.419M $3.022M
YoY Change 343.95% 112.39%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $44.57K $42.06K $307.9K
YoY Change -85.15% -86.34%
Total Long-Term Liabilities $44.57K $42.06K $307.9K
YoY Change -85.15% -86.34%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.952M $6.419M $3.022M
Total Long-Term Liabilities $44.57K $42.06K $307.9K
Total Liabilities $12.23M $9.163M $3.330M
YoY Change 379.67% 175.14%
SHAREHOLDERS EQUITY
Retained Earnings -$96.11M -$89.91M -$73.04M
YoY Change 24.87% 23.09%
Common Stock $128.9M $128.5M $29.43K
YoY Change 324130.16% 436622.56%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $31.48M $37.29M $11.15M
YoY Change
Total Liabilities & Shareholders Equity $43.71M $46.45M $14.48M
YoY Change 20.75% 220.87%

Cashflow Statement

Concept 2016 Q3 2016 Q2 2015 Q2
OPERATING ACTIVITIES
Net Income -$6.196M -$5.883M -$3.530M
YoY Change 57.98% 66.66% 22.5%
Depreciation, Depletion And Amortization $100.0K -$10.00K $70.00K
YoY Change 25.0% -114.29% -22.22%
Cash From Operating Activities -$3.580M -$6.110M -$2.960M
YoY Change 1.42% 106.42% -1.0%
INVESTING ACTIVITIES
Capital Expenditures -$200.0K -$50.00K -$30.00K
YoY Change 0.0% 66.67%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$200.0K -$50.00K -$30.00K
YoY Change 0.0% 66.67%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -60.00K 15.28M -170.0K
YoY Change -100.23% -9088.24% -113.93%
NET CHANGE
Cash From Operating Activities -3.580M -6.110M -2.960M
Cash From Investing Activities -200.0K -50.00K -30.00K
Cash From Financing Activities -60.00K 15.28M -170.0K
Net Change In Cash -3.840M 9.120M -3.160M
YoY Change -117.41% -388.61% 78.53%
FREE CASH FLOW
Cash From Operating Activities -$3.580M -$6.110M -$2.960M
Capital Expenditures -$200.0K -$50.00K -$30.00K
Free Cash Flow -$3.380M -$6.060M -$2.930M
YoY Change 1.5% 106.83% -2.01%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2016Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
43058827 shares
CY2015Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10027305
CY2016Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
690733
CY2016Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2016Q2 us-gaap Cash
Cash
40374433
CY2016Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
43058827 shares
CY2016Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
43058827 shares
CY2016Q2 us-gaap Assets
Assets
46454576
CY2016Q2 us-gaap Assets Current
AssetsCurrent
43880323
CY2016Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2016Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2016Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
128484390
CY2016Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
40374433
CY2016Q2 us-gaap Common Stock Value
CommonStockValue
43059
CY2016Q2 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2016Q2 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2701626
CY2016Q2 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1638220
CY2016Q2 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2455728
CY2016Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
355753
CY2016Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1325774
CY2016Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2325395
CY2016Q2 us-gaap Stockholders Equity
StockholdersEquity
37291544
CY2016Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-89910136
CY2016Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3505890
CY2016Q2 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
245175
CY2016Q2 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
2325395
CY2016Q2 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
899579
CY2016Q2 us-gaap Liabilities
Liabilities
9163032
CY2016Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46454576
CY2016Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
42063
CY2016Q2 us-gaap Liabilities Current
LiabilitiesCurrent
6419343
CY2016Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
134155
CY2016Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
127336
CY2016Q2 us-gaap Preferred Stock Value
PreferredStockValue
5
CY2016Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2446917
CY2014Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18474211
CY2015Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
704597
CY2015Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2015Q4 us-gaap Cash
Cash
29349124
CY2015Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39833023 shares
CY2015Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39833023 shares
CY2015Q4 us-gaap Assets
Assets
33950061
CY2015Q4 us-gaap Assets Current
AssetsCurrent
31660509
CY2015Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
0
CY2015Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000 shares
CY2015Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
112226723
CY2015Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
29349124
CY2015Q4 us-gaap Common Stock Value
CommonStockValue
39833
CY2015Q4 us-gaap Debt Instrument Fair Value
DebtInstrumentFairValue
0
CY2015Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1058536
CY2015Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
194790
CY2015Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1272574
CY2015Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1739380
CY2015Q4 us-gaap Liabilities
Liabilities
2821768
CY2015Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
33950061
CY2015Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
23852
CY2015Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2797916
CY2015Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
194694
CY2015Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
126781
CY2015Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2162771
CY2015Q4 us-gaap Stockholders Equity
StockholdersEquity
31128293
CY2015Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-79865689
CY2015Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2311385
CY2015Q4 pirs Accrued Tax Audit And Legal Fees
AccruedTaxAuditAndLegalFees
179223
us-gaap Depreciation
Depreciation
154555
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7735330
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-4223
us-gaap Revenues
Revenues
377864
CY2015Q4 pirs Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
1739380
CY2015Q4 pirs Accrued Research And Development Costs
AccruedResearchAndDevelopmentCosts
466076
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-8446906
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
485374
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4363405
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-524998
us-gaap Interest Paid
InterestPaid
4224
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
5253
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
897130
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
30481
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-500597
us-gaap Operating Expenses
OperatingExpenses
7613627
us-gaap Net Income Loss
NetIncomeLoss
-7234733
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-7234733
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-74286
us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
-2365
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1397628
us-gaap Operating Income Loss
OperatingIncomeLoss
-7235763
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-1171170
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-500597
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6676452
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
74286
us-gaap Repayments Of Debt
RepaymentsOfDebt
1171170
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0179 pure
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7507 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.82
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3250222
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0149 pure
us-gaap Share Based Compensation
ShareBasedCompensation
485374
us-gaap Restricted Stock Expense
RestrictedStockExpense
390734
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7343 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29361566 shares
pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
0
dei Entity Registrant Name
EntityRegistrantName
PIERIS PHARMACEUTICALS, INC.
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001583648
dei Document Period End Date
DocumentPeriodEndDate
2016-06-30
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
11025309
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.25
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
980229
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2016
dei Amendment Flag
AmendmentFlag
false
us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
0
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4336100
us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents Continuing Operations
EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations
-47401
us-gaap Depreciation
Depreciation
82757
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-10097507
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
us-gaap Revenues
Revenues
2319506
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
131819
us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
350542
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
580908
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-53200
us-gaap Operating Expenses
OperatingExpenses
12495632
us-gaap Net Income Loss
NetIncomeLoss
-10044307
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10044307
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-124608
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1144900
us-gaap Operating Income Loss
OperatingIncomeLoss
-10176126
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
15280672
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-53200
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5111418
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4083354
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
124608
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0161 pure
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Use of estimates</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The preparation of the condensed consolidated financial statements in accordance with U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the reported amounts of revenues and expenses in the financial statements and disclosures in the accompanying notes. Significant estimates are used for, but are not limited to, revenue recognition, deferred tax assets, liabilities and valuation allowances, fair value of stock options and various accruals. Management evaluates its estimates on an ongoing basis. Actual results and outcomes could differ materially from management&#x2019;s estimates, judgments and assumptions.</p> </div>
us-gaap Sales Revenue Goods Net
SalesRevenueGoodsNet
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7600 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.01
dei Trading Symbol
TradingSymbol
PIRS
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8159532
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0113 pure
us-gaap Share Based Compensation
ShareBasedCompensation
980228
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7512 pure
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40347816 shares
pirs Property And Equipment Included In Accounts Payable
PropertyAndEquipmentIncludedInAccountsPayable
207068
pirs Proceeds From Issuance Of Common And Redeemable Convertible Preferred Stock
ProceedsFromIssuanceOfCommonAndRedeemableConvertiblePreferredStock
15280672
CY2016Q2 us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
1 shares
CY2016Q2 pirs Warrant Exercisable Period
WarrantExercisablePeriod
P5Y
CY2015Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
CY2015Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
268039
CY2015Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1969082
CY2015Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3427864
CY2015Q2 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-53
CY2015Q2 us-gaap Revenues
Revenues
160244
CY2015Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
4484
CY2015Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
102135
CY2015Q2 us-gaap Operating Expenses
OperatingExpenses
3694674
CY2015Q2 us-gaap Net Income Loss
NetIncomeLoss
-3529999
CY2015Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3529999
CY2015Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3534430
CY2015Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
102135
CY2015Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0179 pure
CY2015Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7507 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2015Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.81
CY2015Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1725592
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0149 pure
CY2015Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7343 pure
CY2015Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29429522 shares
CY2016Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.14
CY2016Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
611845
CY2016Q2 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
0
CY2016Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2368217
CY2016Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-5777041
CY2016Q2 us-gaap Revenues
Revenues
1072862
CY2016Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-87801
CY2016Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
106212
CY2016Q2 us-gaap Operating Expenses
OperatingExpenses
6868314
CY2016Q2 us-gaap Net Income Loss
NetIncomeLoss
-5883253
CY2016Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5883253
CY2016Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-5795452
CY2016Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
106212
CY2016Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0149 pure
CY2016Q2 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7553 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000 pure
CY2016Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
1.09
CY2016Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4500097
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0113 pure
CY2016Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7512 pure
CY2016Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
40862608 shares

Files In Submission

Name View Source Status
0001193125-16-679305-index-headers.html Edgar Link pending
0001193125-16-679305-index.html Edgar Link pending
0001193125-16-679305.txt Edgar Link pending
0001193125-16-679305-xbrl.zip Edgar Link pending
d229960d10q.htm Edgar Link pending
d229960dex101.htm Edgar Link pending
d229960dex31.htm Edgar Link pending
d229960dex311.htm Edgar Link pending
d229960dex312.htm Edgar Link pending
d229960dex321.htm Edgar Link pending
d229960dex322.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
g229960ex31pg01a.jpg Edgar Link pending
g229960ex31pg01b.jpg Edgar Link pending
g229960ex31pg01c.jpg Edgar Link pending
pirs-20160630.xml Edgar Link completed
pirs-20160630.xsd Edgar Link pending
pirs-20160630_cal.xml Edgar Link unprocessable
pirs-20160630_def.xml Edgar Link unprocessable
pirs-20160630_lab.xml Edgar Link unprocessable
pirs-20160630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending